Semax: The Complete Guide

Semax: The Complete Guide

For research and educational purposes only. Nothing in this guide constitutes medical advice. Consult a qualified healthcare professional before beginning any new protocol. Semax is discussed here as a research compound and is not approved by Health Canada or the FDA for the research applications described in this guide.

Last updated: July 2026

---

Semax is unlike almost everything else in this guide series in one specific way: it isn’t a research chemical with a thin, ambiguous history hoping to become a real drug someday. It already is one — just not in the country most readers live in. Understanding what that actually means, and what it doesn’t, is the key to using this guide well.

Quick Facts

Class	Synthetic ACTH(4-10) analog
Structure	ACTH(4-10) fragment plus a Pro-Gly-Pro extension for stability
Primary research use	Cognitive enhancement, focus, neuroprotection
Administration	Subcutaneous or intranasal
Typical effective range (community-reported)	300mcg once daily
Evidence tier	Genuine, decades-long approved clinical use in Russia; evidence quality doesn’t meet Western regulatory standards
Regulatory status	Approved in Russia since 1994; not approved in the US, Canada, or EU; not on the WADA Prohibited List

The Story So Far

Semax was developed in the 1980s at the Institute of Molecular Genetics of the Russian Academy of Sciences in Moscow, built around a specific fragment of adrenocorticotropic hormone (ACTH) — the same hormone system involved in the body’s stress response. Researchers found that a small piece of ACTH, the 4-10 fragment, retained activity at melanocortin receptors relevant to attention, learning, and memory, without the adrenal steroidogenic effects (the hormonal cascade that gives full ACTH its stress-response role) that would make the intact hormone impractical as a cognitive research tool. To make that fragment last longer in the body, researchers attached a short tripeptide extension — proline-glycine-proline — to the end of it, which is what actually distinguishes Semax as a distinct, engineered compound rather than simply “a piece of ACTH.”

This wasn’t an obscure academic exercise that stayed in a lab. The Russian Ministry of Health approved Semax in 1994 for cerebrovascular and cognitive indications, and it has been used continuously in Russian clinical practice for over three decades since — for ischemic stroke recovery, cognitive decline, encephalopathy, and optic nerve conditions. It remains on Russia’s official Vidal pharmaceutical register today. This is a genuinely different regulatory story than almost any other compound in this guide series: Semax isn’t an unapproved research chemical everywhere in the world, it’s an approved pharmaceutical in one major country and an unapproved research compound in most others, including Canada and the United States.

That regulatory gap has narrowed somewhat in the United States, at least on the compounding side, as of 2026 — worth knowing as context even though it doesn’t create a parallel pathway in Canada. On February 27, 2026, U.S. Health and Human Services Secretary Robert F. Kennedy Jr. announced — during an appearance on the Joe Rogan Experience — that approximately 14 of 19 peptides previously restricted under the FDA’s Category 2 compounding classification, including Semax, would move back toward Category 1 status. The FDA formalized Semax’s removal from Category 2 on April 15, 2026. A Pharmacy Compounding Advisory Committee meeting scheduled for July 23–24, 2026 will specifically evaluate Semax for potential addition to the FDA’s list of approved bulk substances for compounding, with cerebral ischemia, migraine, and trigeminal neuralgia named as the specific indications under review. This American compounding-pharmacy pathway has no direct equivalent in Canada — see our Canadian regulatory guide for the framework that actually applies here.

One more regulatory point worth knowing directly: as of April 2026, Semax is not included on the World Anti-Doping Agency’s Prohibited List — a genuine distinction from several other compounds covered elsewhere in this guide series, including BPC-157, TB-500, CJC-1295, and Ipamorelin, all of which are prohibited for tested athletes. This isn’t a guarantee that status won’t change, and athletes subject to testing should always confirm current status with their governing body, but it’s worth knowing Semax doesn’t currently carry the same anti-doping exposure as several of its research-peptide counterparts.

What It Actually Does

Semax’s primary, best-established mechanism is upregulating brain-derived neurotrophic factor (BDNF) — a protein that supports the survival, growth, and connectivity of neurons, and that plays a central role in learning and memory. Compounds that reliably elevate BDNF are relatively uncommon, and this is the finding that anchors most of Semax’s reputation in both Russian clinical use and international nootropic research interest.

Beyond BDNF, Semax modulates neuroinflammation and has documented effects on serotonergic and dopaminergic signaling — the neurotransmitter systems most associated with mood and motivation. More recent preclinical work has identified additional, more specific mechanisms: a 2025 study found Semax promotes a cellular process called deubiquitination of mu opioid receptors, stabilizing lysosomal membranes in the context of spinal cord injury recovery in mice — a genuinely novel mechanistic finding distinct from the BDNF story, suggesting Semax’s activity may be broader than its original characterization captured.

What the Research Shows

Semax’s evidence picture is unusual in this guide series for a specific reason: it isn’t thin, it’s extensive — just conducted almost entirely outside the framework Western regulators and researchers use to evaluate evidence quality.

The clinical use history in Russia is genuinely substantial. Decades of use for stroke recovery, cognitive decline, and optic nerve conditions, backed by a real regulatory approval and continued inclusion on Russia’s pharmaceutical register, reflects a level of sustained clinical confidence that most unapproved research compounds in this guide series don’t have. This is real clinical history, not a marketing claim.

That history comes with a specific, honest caveat. Russian clinical research from this era doesn’t always meet the design standards Western regulatory agencies require — smaller sample sizes, inconsistent use of placebo controls and blinding, and full trial protocols that aren’t always available in English are all genuine limitations affecting how confidently this body of work can be evaluated by outside researchers. This doesn’t mean the findings are fabricated; it means they sit in a different evidentiary category than a modern, Western-registered randomized controlled trial, and it’s worth holding that distinction clearly rather than treating “decades of Russian clinical use” as equivalent to “Phase 3 trial data.”

Western preclinical research has replicated core parts of the story. The BDNF elevation and neuroprotective effects have been confirmed in animal models outside Russia, and recent additions extend the picture further: a 2025 study in the British Journal of Pharmacology found Semax promoted recovery after spinal cord injury in mice through the opioid-receptor mechanism described above, and a separate 2025 study in Acta Naturae explored Semax’s effects on amyloid aggregation and neuroinflammation in an Alzheimer’s disease mouse model. Both are genuinely current, peer-reviewed additions to the preclinical case, though — as animal studies — they don’t resolve the human evidence-quality question above.

How It Compares

Semax sits alongside Selank in the cognitive category. For the full comparison, see our Selank guide. The short version: Semax is activating — it upregulates BDNF and tends to increase alertness and cognitive engagement — while Selank is calming, working through GABAergic and serotonergic modulation to reduce anxiety without sedation. They come from the same Russian research tradition and share the same evidence-quality profile and limitations, but their current regulatory paths have actually diverged: Semax is under active FDA review toward a possible US compounding pathway, while Selank’s nomination for that same process was withdrawn in 2024, leaving it without a current path forward. That’s US-specific detail with no bearing on the Canadian legal picture, but worth knowing if you see the two treated as regulatory equivalents elsewhere. They’re frequently discussed together as complementary rather than competing tools — Semax for cognitive engagement, Selank for the anxiety reduction that can otherwise undercut it.

Who Shouldn’t Use This

Semax has no FDA or Health Canada approval, so there’s no official North American contraindications list — its Russian approval carries its own labeled contraindications, but those don’t map directly onto research-compound use outside that regulatory context. Based on the available literature:

• History of seizure disorders. As a neurologically active compound, Semax should be approached with particular caution and medical guidance by anyone with a seizure history.
• Pregnancy or breastfeeding. No adequate safety data exists in this context.

Beyond these, no established absolute contraindications exist in the available literature at community research ranges — though, as with the evidence discussion above, this reflects a specific kind of data (extensive Russian clinical use, thinner Western-standard confirmation) rather than a clean, comprehensively documented safety profile by the standards applied elsewhere in this guide series.

Common Myths, Addressed

“Since it’s been approved in Russia since 1994, it meets the same evidence bar as an FDA-approved drug.” Not accurately. Russia’s regulatory framework has historically used different, often less stringent clinical evidence requirements than FDA or EMA standards — a real approval, but not evidence of the same rigor.

“Semax is banned for athletes like most other peptides in this category.” Not currently — as of April 2026, it isn’t on the WADA Prohibited List, unlike several other compounds covered elsewhere in this guide series. Status can change, so this is worth confirming directly if you’re subject to testing, but it’s not currently a concern the way it is for BPC-157 or the GH-axis compounds.

“Decades of use in Russia proves it’s both safe and effective.” Sustained clinical use is a meaningful, genuine signal — it’s not nothing. But it’s a different claim than “demonstrated in a well-controlled trial by Western standards,” and the two shouldn’t be treated as interchangeable when you’re weighing how much confidence to place in the evidence.

What Researchers Are Actually Experiencing

Semax is consistently described in community discussion as activating rather than calming — increasing alertness and cognitive engagement, which is why morning administration is the overwhelming community norm, and why evening use is generally avoided given its potential to interfere with sleep onset.

Mild stimulation or, less commonly, mild anxiety is occasionally reported, particularly at higher doses or in researchers who are generally sensitive to nootropic compounds — consistent with its effects on serotonergic and dopaminergic signaling. Nasal irritation is occasionally reported specifically with intranasal use.

The choice between subcutaneous and intranasal administration comes up frequently in community discussion. Intranasal delivery has a real mechanistic argument behind it — partial direct access to the central nervous system via the olfactory pathway, bypassing some of the standard systemic absorption process — while subcutaneous injection is simpler to prepare and equally well-documented in community use.

This section reflects patterns commonly discussed across community research spaces. It’s observational rather than clinical trial data, and individual experience varies.

The Practical Basics

Research Ranges

Route	Research Range	Frequency
Subcutaneous — standard	300mcg	Once daily
Subcutaneous — range	100–600mcg	Once daily, depending on response
Intranasal	200–500mcg	Once daily, divided across nostrils
Conservative start	100mcg	Once daily, either route

300mcg once daily is a solid starting point for most researchers. Individual response varies more with this compound than with most others in this guide series — some researchers find 500mcg their effective dose, others stay at 100–200mcg. Start conservatively and adjust based on how you feel.

Worked Dose Math

At 5mg/mL (a 10mg vial — standard 3mL vial capacity — reconstituted with 2mL BAC water):

• 100mcg (0.1mg) → 0.02mL → 2 units
• 300mcg (0.3mg) → 0.06mL → 6 units
• 500mcg (0.5mg) → 0.1mL → 10 units

The underlying rule: volume (mL) = dose (mg) ÷ concentration (mg/mL), then ×100 for units on a U-100 syringe. Research ranges here are in micrograms — convert to milligrams before applying the formula.

Vial Planning

A 10mg vial at 5mg/mL gives you 10mg total. At a steady 300mcg/day, that’s a little over 33 days per vial.

Reconstitution and Storage — The Short Version

Semax reconstitutes with standard BAC water, refrigerates at 2–8°C, and should be used within 28 days. For the complete process, see our dedicated reconstitution and storage guide. Note that intranasal preparation typically uses a different concentration and delivery format than the subcutaneous approach described above — vendors carrying intranasal Semax generally supply it in a format specific to that route.

Sourcing

Nothing Semax-specific beyond the general picture — see our full guide on reading a Certificate of Analysis and vetting a vendor.

Administration

Once daily, morning. Subcutaneous injection or intranasal drops/spray. No fasting requirement.

Best Practices

• Administer in the morning, given the activating profile — evening use is more likely to interfere with sleep for most researchers.
• Start conservative and adjust individually — response variance is genuinely wider here than for most compounds in this guide series.
• Choose your route based on your actual priority — intranasal for the CNS-delivery rationale, subcutaneous for simplicity — rather than assuming one is categorically superior.
• Track your protocol from day one — dose, route, timing, and observed effects, at minimum.

Common Mistakes to Avoid

• Assuming Russian regulatory approval is equivalent to FDA or Health Canada approval — it reflects a different evidentiary framework, not an equivalent one.
• Administering in the evening and then being surprised by disrupted sleep.
• Not recording the reconstitution volume, turning every dose calculation into a guess.
• Assuming a fixed effective dose applies to you without adjusting based on your own individual response.

What Happens If You Stop

There’s no dedicated discontinuation research specific to this question. Given that Semax is most commonly used for a defined cognitive-performance objective — a demanding work period, a specific research window — rather than as an indefinite standing intervention, most community use frames discontinuation as simply the natural end of a use period rather than something expected to produce a rebound effect. This is consistent with how it’s actually used in practice rather than a documented pharmacological finding.

What to Expect, Week by Week

• Day 1: Effects are often reported within hours of the first dose, given the compound’s relatively fast-acting profile relative to others in this guide series.
• Weeks 1–2: Most researchers use this window to find their individual effective dose, given how much response varies person to person.
• Ongoing: Many researchers use Semax situationally — on demanding cognitive days — rather than as a continuous daily addition, though daily protocols are also common.

Individual timelines vary substantially, and this pattern comes primarily from community report for the specific research use cases discussed here.

Combining With Other Compounds

Semax’s most common pairing is Selank, for what community discussion describes as a “calm focus” combination — Semax’s activating, attention-supporting profile alongside Selank’s anxiety-reducing, non-sedating calm. The rationale is complementary rather than redundant: Semax alone can feel edgy or overstimulating for some researchers at higher doses, and Selank alone may feel insufficiently activating for a cognitive-performance objective. Together, community discussion describes a steadier, more sustainable state than either compound produces alone — a community observation, not a clinically validated finding.

Common Questions

Is Semax actually a real, approved drug somewhere? Yes — it’s been approved in Russia since 1994 for stroke recovery, cognitive decline, and related neurological conditions, and remains on Russia’s official pharmaceutical register today. It has no equivalent approval in Canada, the US, or the EU.

Can I get this legally in Canada? See our Canadian regulatory guide for the general legal framework that applies to research peptides here. For context, the US situation is different and not directly transferable: American researchers gained a narrow prescription pathway through licensed compounding pharmacies following Semax’s April 2026 removal from FDA Category 2 restrictions, but that mechanism doesn’t have a Canadian equivalent.

Is Semax banned for athletes? Not currently — as of April 2026, it isn’t on the WADA Prohibited List, unlike several other compounds in this guide series. Confirm current status directly if you’re subject to testing.

Why does Semax’s evidence get described as both extensive and limited at the same time? Because both are true in different senses — extensive in terms of duration and real clinical use in Russia, limited in terms of meeting the trial-design standards (blinding, placebo control, sample size, published protocol availability) that Western regulators and researchers typically require.

Before You Start

A quick checklist to run through before your first dose:

• [ ] Considered whether you have a seizure disorder history, and sought medical guidance if so
• [ ] Decided on a route (subcutaneous or intranasal) based on your specific priority
• [ ] Planned for morning administration given the activating profile
• [ ] Have a tracking method ready for dose, route, and observed effects
• [ ] Understand the evidence base is extensive in duration but doesn’t meet Western trial-design standards

Want this as a printable checklist alongside our compound reference plate? Download both from the resources section.

Common Protocol at a Glance

Route	Dose	Frequency
Conservative start	100mcg	Once daily
Standard	300mcg	Once daily, morning
Intranasal	200–500mcg	Once daily, divided across nostrils

Where to Go From Here

• The Cognitive Compound Group — Semax and Selank compared in full
• Our Canadian Regulatory Landscape Guide
• Our Reconstitution and Storage Guide
• Our Certificate of Analysis and Vendor Verification Guide

---

This guide reflects the evidence and community research patterns available as of publication and will be updated periodically as new research emerges. It is provided for research and educational purposes only, does not constitute medical advice, and is not a substitute for consultation with a qualified healthcare professional. Aethon Labs does not intend for any compound discussed here to be used for human consumption.

AETHON LABS — Tested. Documented. Delivered.